Iktos
Pierre Grenut's work experience includes roles as a Business Development Analyst and Business Development Intern at Iktos, a Business Developer at Labtoo, the President of iGEM Sorbonne Université, and a Trainee at Inserm and Faculdade de Ciências da Universidade de Lisboa. Pierre started working at Iktos in 2021 as a Business Development Analyst, and previously held the position of Business Development Intern. From 2019 to 2020, they worked as a Business Developer at Labtoo. In 2019, they were the President of iGEM Sorbonne Université, and during the same year, they also worked as a Trainee at Inserm. In 2017, they had a trainee position at Faculdade de Ciências da Universidade de Lisboa.
Pierre Grenut has a robust education history in the fields of pharmaceutical and biotechnology management, cellular and molecular biology, and chemistry. From 2020 to 2021, Pierre Grenut attended ESCP Business School, where they pursued a Specialised Master's degree in Pharmaceutical & Biotechnology Management. Prior to that, from 2018 to 2020, they pursued a Master's degree in Cellular and Molecular Biology at Sorbonne Université. Additionally, Pierre obtained a Bachelor's degree, known as a Licence, from Sorbonne Université in two different fields of study. From 2015 to 2018, they obtained a Licence in General Biology, and during the same period, they also earned a Licence in Chemistry. These educational experiences indicate a strong foundation in various scientific disciplines, providing Pierre Grenut with a well-rounded academic background.
This person is not in any offices
Iktos
Incorporated in October 2016, Iktos is a start-up company specializing in the development of artificial intelligence solutions applied to chemical research, more specifically medicinal chemistry and new drug design. Iktos is developing a proprietary and innovative solution based on deep learning generative models, which enables, using existingdata, the design of molecules that are optimized in silico to meet all the success criteria of a small molecule discovery project. The use of Iktos technology enables major productivity gains in upstream pharmaceutical R&D. Iktos offers its technology both as a professional services and as a SaaS software platform. Iktos offers Makya™, ligand and structure-based de novo drug design platform for multi-parametric optimisation (MPO) of lead compounds in line with Target Candidate Profile (TCP). Iktos is also developing Spaya™, a synthesis planning software based upon Iktos’s proprietary AI technology for retrosynthesis.